Search research articles
Contact Us
Filters
Showing results (81-90 of 119) with videos related to
Page
of 12
Sort By:
British Journal of Haematology
|
September 11, 2025
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia
Christina Poh, Xueyan Chen, Jenna Voutsinas, et al.
Blood
|
February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G Till, Michael C Jensen, Jinjuan Wang, et al.
JCO Clinical Cancer Informatics
|
January 14, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models
Emily C Liang, Yein Jeon, Yang Qiao, et al.
Blood Advances
|
September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Emily C Liang, Aya Albittar, Jennifer J Huang, et al.
Blood Advances
|
October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Mazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
Blood
|
May 30, 2008
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G Till, Michael C Jensen, Jinjuan Wang, et al.
Hematological Oncology
|
September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status
Maika Onishi, Solomon A Graf, Leona Holmberg, et al.
Leukemia & Lymphoma
|
April 9, 2014
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity
Colin Phipps, Ajay K Gopal, Barry E Storer, et al.
Blood
|
August 10, 2019
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
Shyril O'Steen, Melissa L Comstock, Johnnie J Orozco, et al.
Blood
|
November 22, 2017
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies
Damian J Green, Shyril O'Steen, Yukang Lin, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 119) with videos related to
Sort By:
Page
of 12
British Journal of Haematology
|
September 11, 2025
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia
Christina Poh, Xueyan Chen, Jenna Voutsinas, et al.
Blood
|
February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G Till, Michael C Jensen, Jinjuan Wang, et al.
JCO Clinical Cancer Informatics
|
January 14, 2026
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models
Emily C Liang, Yein Jeon, Yang Qiao, et al.
Blood Advances
|
September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Emily C Liang, Aya Albittar, Jennifer J Huang, et al.
Blood Advances
|
October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Mazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
Blood
|
May 30, 2008
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G Till, Michael C Jensen, Jinjuan Wang, et al.
Hematological Oncology
|
September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status
Maika Onishi, Solomon A Graf, Leona Holmberg, et al.
Leukemia & Lymphoma
|
April 9, 2014
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity
Colin Phipps, Ajay K Gopal, Barry E Storer, et al.
Blood
|
August 10, 2019
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
Shyril O'Steen, Melissa L Comstock, Johnnie J Orozco, et al.
Blood
|
November 22, 2017
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies
Damian J Green, Shyril O'Steen, Yukang Lin, et al.
Page
of 12